Analysts Think This Soaring Cathie Wood Stock Has Peaked. Are They Right?
It's been a good start to the year for Cathie Wood's ARK Innovation ETF, which is up 36% thus far in 2023. The fund has benefited as growth stocks have been getting back into the good graces of investors thanks partly to excitement over artificial intelligence as well as hopes that interest rates may have peaked.
But one stock in this ETF that Wall Street analysts don't feel particularly bullish on right now is Exact Sciences (NASDAQ: EXAS). On average, they believe the stock has hit a peak as it is past many price targets. Should investors be concerned, and is this a reason to avoid the stock?
Exact Sciences is in the business of cancer screening. Its Cologuard test is non-invasive and can help with the early detection of colorectal cancer. The company also has other tests as it hopes to help prevent cancer-related deaths.
Source Fool.com
